Opioid Induced Constipation Market Analysis, Demand, Growth Opportunities and Recent Trends by Leading Manufacturers and Regions
Pramod KmrMarch 01, 2019Induced Constipation Market, Induced Constipation Market Demand, Induced Constipation Market Growth, Induced Constipation Market Share, Induced Constipation Market Size, Trends
1 comment
Opioids are
directed to the patients suffering from the acute and chronic non-cancer pain.
The opioids have numerous adverse intestinal effects, such as opioid-induced
constipation. The opioids also affect the discharge of digestive enzymes that
can sometime cause partial gastro paresis. Some of the most familiar symptoms
of opioid-induced constipation includes, hard and dry stools, swelling, painful
defecation, distention and protruded abdomen, tiredness, and loss of hunger.
Some of the most common opioid-induced constipation therapy is the use of
targeted therapies, OTC and off-label drugs and changing lifestyle.
On the
basis of different form of drug the global opioid-induced constipation market
can be bifurcated into two broad categories: solid and liquid. Some of the
dominant market drivers for opioid-induced constipation includes, rising number
of OIC patients, and widespread use of opioids treatment in chronic non-cancer
pain. The current opioid-induced constipation market is led by the inexpensive
and widely available laxatives. The clinical efficiency of laxatives is poor
compared to its counterparts; however they still broadly used in constipation
relief.
Lack of
awareness about the opioid-induced constipation in patients, and the doctors
are one of the dominant causes of off-label and OIC medications as majorly used
treatment methods. However, the efficiency of these drugs is only the half of
some of the other therapies. The entrance of superficially acting mu-opioid
receptor rivals such as Movantikv or Moventig are driving the opioid-induced
constipation market. Movantikv or Moventig drug targets only the fundamental
reason of opioid-induced constipation without affecting the effect of the
opioid drugs.
Request to Get the
Sample Pages at:
Europe was
the largest market of the opioid-induced constipation market in 2015 in terms
of value. It is then followed by North America. The market dominance of Europe
is attributed the presence of a large number of baby boomers population in the
region. North America was the fastest growing market for opioid-induced
constipation in 2014, the market size of North America is expected to surpass
the Europe during the forecast period. The high growth of the market is
attributed to the supportive government incentive in healthcare services in
addition with the presence of a large pool of patients suffering from chronic
pain.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=opioid-induced-constipation-market
In
September 2014 the U.S. Food and Drug Administration (FDA) has approved methyl
naltrexone bromide hypodermic injection, 12 mg/0.6ml, for the treatment of
opioid-induced constipation for the patients using opioids non-cancer chronic
pain. This approval from the FDA is expected to serve approx. 11 million
patients in the U.S. who are suffering from opioid-induced constipation.
Based on
the different form of therapy the global opioid-induced constipation market can
be broadly categorized as non-tamper resistant formulations (non-TRFs) and
tamper resistant formulations (TRF). The non-TRFs has the largest market share
in 2014, however the TRFs is expected to more dominant treatment technology in
upcoming years attributed mainly to the U.S. Food and Drug Administration (FDA)
promotions and broad pipeline of oral
(TRFs) approval.
Some of the
major players operating in the global
opioid-induced constipation market include, AstraZeneca plc, Valeant
Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix
Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and
Bayer AG among others.
Glaucoma Therapeutics Market Demand, Developments, Industry Opportunities and Industry Research Report
Pramod KmrMarch 01, 2019Demand, Glaucoma Therapeutics Market, Glaucoma Therapeutics Market Growth, Glaucoma Therapeutics Market Share, Glaucoma Therapeutics Market Size, Outlook, Research Report
1 comment
Glaucoma is
a disease of eye which is caused by excessive increase of fluid pressure within
the eye. Glaucoma is caused due to mechanical compression or decreased blood
flow in the optic nerve of the patient’s eye. If not treated properly, it may
lead to mild loss of vision and even blindness. Treatment of glaucoma includes
laser therapies, pharmaceutical drugs and surgical procedures.
Ocular
hypertension is one of the major causes due to which glaucoma occurs in
patients. Glaucoma mostly occurs at the age over 40, but it may also occur in
children, young adults, and infants. Diagnosis of glaucoma can be done through
a simple eye examination with the help of tonometry, an instrument used for
measuring intraocular pressure, by an ophthalmologists and optometrist.
Prevention of glaucoma is difficult; however, if diagnosed and treated at an
early stage, the disease can be controlled by using eye drops prescribed by
doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the
affected eye permanently; in first stage it decreases the peripheral vision and
if not treated, it can lead to blindness.
Request to Get the
Sample Pages at:
Some of the
major factors driving the growth of glaucoma therapeutics market are aging
population of developed countries, development of advanced glaucoma drug
delivery devices and rising global healthcare expenditures. Stringent
government regulation and marketing approval, side effects of glaucoma
medications and long development process of the glaucoma products are some of
the major factors restraining the growth of global glaucoma therapeutics
market.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=glaucoma-therapeutics-market
North
America was the largest glaucoma therapeutics market in 2014, attributed to
high per capita expenditure on healthcare in this region. It is followed by
Europe and Asia-Pacific. Asia-Pacific region is also the fastest growing
glaucoma therapeutics market, owing to the aging population of Japan coupled
with the increasing healthcare expenditure of developing countries, such as
India and China. Asia-Pacific glaucoma therapeutics market is further expected
to witness growth and surpass North America market in terms of largest market during
the coming years.
Some of the
major competitors in global glaucoma therapeutics market are Pfizer Inc.,
Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc.,
Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals
Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co.
Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals
International Inc.
Testicular Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand
Pramod KmrMarch 01, 2019Growth, Outlook, Research Report, Testicular Cancer Therapeutics Market, Testicular Cancer Therapeutics Market Demand, Testicular Cancer Therapeutics Market Share, Testicular Cancer Therapeutics Market Size
1 comment
Global
testicular cancer therapeutics market is growing with the increasing prevalence
of testicular cancer. The market is expected to witness moderate growth, since
there are already more than 15 drugs that exist in the market for the treatment
of testicular cancer. Increasing prevalence of cancer and rising demand for the
medications with better efficacy and less side effects can be attributed as an
opportunity for oncology. The regulatory bodies such as USFDA, EMA are
supporting the growth of the global market by providing increased funding,
designations and grants for speeding up the drug development process.
Testicular
cancer is the tumor that develops in the testicles. Testicles are the glands
found in men that produce testosterone hormone and sperms. The cause of
testicular cancer is attributable to enormous growth of testicular cells due to
some abnormalities, resulting in the formation of tumor in testicles, causing
testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities,
abnormal testicular development and family history can increase the risk of
testicular cancer. Mumps orchitis are also one of risk factors which is a very
rare complication of mumps, which involves the inflammation of testicles. Pain,
swelling, discomfort, sensation of heaviness and sudden fluid accumulation in
scrotum are the main symptoms of testicular cancer.
Request to Get the
Sample Pages at:
Growing
prevalence of testicular cancer and combination therapies for the treatment are
the major driving forces for the testicular cancer therapeutics market. Also
with no drug in Phase III, there is a need for growth in pipeline for better
treatment options, providing increased opportunities to the players in the
market. Some of the marketed drugs for the treatment of testicular cancer
include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos
(Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate).
Some of the drug combination available in the market are BEP, JEB, PEB, VIP and
VeIP.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=testicular-cancer-therapeutics-market
The
treatment is more effective if the chemotherapy regimen involves two or more
drugs rather than using any single drug. Therefore, chemotherapy is expected to
have major share in the global testicular cancer therapeutics market.
Some of the
key players operating in the global
testicular cancer therapeutics market are Ovation Pharmaceuticals,
Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva
Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral
Medicines, Inc.
Esophageal Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024
Pramod KmrFebruary 26, 2019Esophageal Cancer Therapeutics Market, Esophageal Cancer Therapeutics Market Demand, Esophageal Cancer Therapeutics Market Share, Esophageal Cancer Therapeutics Market Size, Growth, Research Report
No comments
Global
esophageal cancer therapeutics market is expected to witness significant growth
with an increasing awareness regarding cancer treatment and technological
advancements. Also, high demand for safe and effective medications and rising
prevalence of cancer are driving the growth of the global market. The
regulatory bodies such as USFDA, EMA are supporting the growth of the global
market by providing funding, designations and grants for speeding up the drug
development process.
Esophageal
cancer involves formation of malignant cells in the tissues of the esophagus.
Esophagus is a muscular tube that enable food and liquids to move from the
throat to the stomach. The main types of esophageal cancer are adenocarcinoma
and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and
release mucus and other fluids. Squamous cell carcinoma forms in flat cells
lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol
consumption and smoking as major risk factors, with gastroesophageal reflux
disease and Barrett esophagus further contributing as the risk factors of
esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms;
therefore, an advanced stage diagnosis is difficult.
Request to Get the
Sample Pages at:
Some of the
major drivers for the global esophageal cancer therapeutics market include
combination therapies, treatment advancements, increasing number of regulatory
approvals for esophageal cancer and a rise in the number of cancer treatment
centers. Moreover, the launch of new drug therapies for esophageal cancer is
expected to contribute as a key market driver in the near future. Also with a
dense pipeline, many new drug candidates are expected to enter the global
esophageal cancer therapeutics market. Safety concerns and efficacy of the
treatment are the major factors that can hinder the market growth over the
forecast period. Other factors hampering the market growth include low
availability of drugs commercially and high cost of therapy for the treatment
of esophageal cancer.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=esophageal-cancer-therapeutics-market
Certain
chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine,
Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine,
Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well
established as a conventional method. Immunotherapy, combination therapy,
monoclonal antibodies and steroids have also been showing good results for the
treatment of esophageal cancer.
Some of the
key players operating in the global esophageal
cancer therapeutics market include Genentech, Inc.,
Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck
& Co., Inc., Johnson & Johnson Pharmaceutical Research &
Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.
Oropharyngeal Cancer Therapeutics Market Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape
Pramod KmrFebruary 24, 2019Oropharyngeal Cancer Therapeutics Market, Oropharyngeal Cancer Therapeutics Market Demand, Oropharyngeal Cancer Therapeutics Market Share, Oropharyngeal Cancer Therapeutics Market Size, Research Report
No comments
The global
oropharyngeal cancer therapeutics market is expected to have
significant growth since the pipeline for oropharyngeal cancer is growing
rapidly.
Also, there
are no specific drugs available for the treatment of oropharyngeal cancer
providing increased opportunities for the major key players.
Oral cavity
tumor or oral tumor, is tumor that begins in the mouth (also known as the oral
cavity). Oropharyngeal malignancy begins in the oropharynx, which is the part
of the throat behind the mouth. The oral cavity comprises of lips, the inside
lining of the lips and cheeks (buccal mucosa), the teeth, the gums, the front
two-thirds of the tongue, the floor of the mouth below the tongue and the bony
roof of the mouth (hard palate). The area behind the wisdom teeth, called the
retromolar trigone is also sometimes included in the oral cavity, though it is
often considered part of the oropharynx.
Request to Get the
Sample Pages at:
The
oropharynx is the part of the throat just behind the mouth and begins where the
oral cavity stops. It comprises of base of the tongue (the back third of the
tongue), the soft palate (the back part of the roof of the mouth), the tonsils,
and the side and back wall of the throat.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oropharyngeal-cancer-therapeutics-market
The
oropharyngeal cancer therapeutics market is segmented based on the therapy
which includes surgery, chemotherapy, radiation therapy, targeted therapy and
palliative treatment. Chemotherapy holds the largest share since it contains
maximum number of drugs including, Cisplatin, Carboplatin, 5-fluorouracil
(5-FU), Paclitaxel (Taxol) and Docetaxel (Taxotere). The palliative treatment
segment holds the second largest share including, ibuprofen, acetaminophen,
morphine or similar drugs. Targeted therapy holds the lowest share and includes
only one drug, Cetuximab which may be combined with radiation therapy.
Some of the
key players operating in the oropharyngeal cancer therapeutics market include
Genticel S.A., AstraZeneca Plc, Kolltan Pharmaceuticals Inc., PNP Therapeutics
Inc., Novartis AG, Advaxis Inc., Merck & Co. Inc., VLPbio and Synta Pharmaceuticals
Corp.
Influenza Vaccine Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape
Pramod KmrFebruary 22, 2019Influenza Vaccine Market, Influenza Vaccine Market Demand, Influenza Vaccine Market Growth, Influenza Vaccine Market Share, Influenza Vaccine Market Size, Outlook, Research Report, Trends
1 comment
The global influenza
vaccine market is growing significantly due increasing awareness about the
pandemic influenza viruses and increasing government involvement for
vaccination against influenza viruses.Massive unexplored influenza vaccine
marketin the emerging economiesare creating ample opportunities for the global
influenza vaccine marketto grow at a significant rate in the forecasted
period.The advanced research and development facilities and new vaccine
developments by the companies are propelling the demand for safe and
efficacious influenza vaccine. Influenza (flu) is a respiratory disease caused
by mainly two types of influenza viruses namely, influenza A and B viruses.
Influenza A viruses are of two types based on the proteins on the surface of
virus: hemagglutinin (H) and neuraminidase (N).
In global
influenza vaccine industry, there is a trend of development of intranasal
vaccine due to the ease of self administration. According to Centers for
Disease Control and Prevention (CDC),in 2009, approximately 151,700 to 575,400
people died due to H1N1 influenza pandemic or swine flu across the globe. In
addition, the organization also reported that most deaths due to 2009 flu
pandemic occurred in Africa and Southeast Asia region. Several vaccines have
been developed to prevent pandemic and seasonal influenza viruses using
recombinant DNA technology and extensive researches are going on to develop
efficient influenza vaccines using cell culture technology. Various
governmental and non-governmental organizations have been actively involved in
promoting and monitoring vaccination programs aimed at immunising people
against seasonal influenza viruses. This in turn fuels the growth of global
influenza vaccine market.
Request to Get the
Sample Pages at:
Some of the
factors driving the growth of the global influenza vaccine market are
increasing research and development activities,increasing investment by
companies for the development of influenza vaccine, technological advancements
in recombinant DNA technology, large number of population with no immunization
against influenza viruses in emerging economies,increasing healthcare
expenditure, and increasing involvement of government and non-government
organizations.In addition, geriatric population and people suffering from
chronic diseases are at higher risk of developing influenza virus infection;
hence, aging population and increasing prevalence of chronic diseases are also
driving the demand of influenza vaccine market. However, stringent regulatory
framework and low accessibility to remote areas aresome of the factors
restraining the growth of the global influenza vaccine market to some extent.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=influenza-vaccine-market
Geographically,
North America will be leading the global influenza vaccine market in the coming
years, due to high awareness of influenza viruses, high healthcare expenditure,
and increasing research and development activities.In addition, the U.S. Food
and Drug Administration (FDA), recommends vaccination as the most effective
method to prevent influenza; hence, fueling the growth of influenza vaccine
market in NorthAmerica region. Asia-Pacificis the fastest growing region in the
global influenza vaccinemarket. The major reasons for the fastest growth in the
region are massive unexplored market (as large number of people donot have
access to vaccination), increasing involvement of government, and increasing
healthcare expenditure.
Some of the
major players operating in the global
influenza vaccine market are GlaxoSmithKline,Sanofi Pasteur, Inc., ID
Biomedical Corporation, CSL Limited, Novartis, Protein Sciences Corporaton,
MedImmune, LLC, Sinovac Biotech, Serum Institute of India, and Hualun
Biologicalsamong others.
Infectious Disease Treatment Market Outlook - Top Companies, Trends and Future Prospects Details for Business Development
Pramod KmrFebruary 21, 2019Growth, Infectious Disease Treatment Market, Infectious Disease Treatment Market Demand, Infectious Disease Treatment Market Share, Infectious Disease Treatment Market Size, Outlook, Research Report
4 comments
Infectious
diseases are medical conditions or disorders caused by microorganisms such as
bacteria, fungi, viruses and other parasites. Several organisms are present in
and on human bodies. Some organisms are normally harmless and even helpful.
However, under certain circumstances, some organisms cause diseases. Infectious
diseases spread from one person to another. Moreover, some are transmitted by
bites from insects and animals. Infectious diseases also occur by consumption
of contaminated food and water.
Signs and
symptoms of infectious diseases depend on the type of organism and infection.
Some of the most common symptoms of infectious diseases include fatigue and
fever. Mild complaints of infectious diseases treated from rest and home
remedies, while some life-threatening infections require hospitalization.
Infectious diseases, such chickenpox and measles are prevented by vaccination.
Frequent and thorough hand-washing also protect human body from infectious
diseases.
Download Report
Sample at:
North
America dominates the global infectious disease treatment market followed by
Europe. The U.S., followed by Canada, is the largest market for infectious
disease treatment in the North American region. Key driving factor for
infectious disease treatment market in the region is increasing research
activities on various types of diseases. Germany, France and the U.K. are some
of the largest markets for infectious diseases in Europe. However, Asia-Pacific
represents the fastest growing region in the global infectious disease
treatment market. This is due to minimal wages and availability of skilled
professionals in the region. These factors attract drug manufacturing companies
to invest in the Asian countries. In addition, in developing countries, such as
China and India, government has launched several programs and initiatives to
increase awareness about infectious diseases. China, Japan and India are
largest infectious disease treatment markets in the region.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=infectious-disease-treatment
Increasing prevalence of the infectious diseases is key driving factor for the global infectious disease treatment market. Increasing awareness and extensive R&D drugs pipelines are also enhancing the growth of global infectious disease market. Moreover, introduction of novel drugs, such as direct-acting antivirals, boosts the growth of global infectious disease treatment market.
However,
patent expiry of various major drugs and presence of generic drugs are key
restraint of the global infectious disease treatment market. Stringent
regulations and legislations and side-effects of anti-infective drugs also
hinder the growth of global infectious disease treatment market. Rapid product
launches and increasing mergers and acquisitions between drug manufactures are emerging
trends of the global infectious disease treatment market.
Some of the
major competitors in the global
infectious disease treatment market are F. Hoffmann-La Roche,
GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, Gilead Sciences, Bristol-Myers Squibb Company, AstraZeneca,
Bayer AG, Novartis, Sanofi, AbbVie and Auritec Pharmaceuticals.
























